Gland Pharma Limited
Mirae Asset Mutual Fund trimmed its Gland Pharma stake from 5.14% to 4.96%, selling 3,00,972 shares via open market and crossing the 5% disclosure threshold.
A vertically integrated injectable-focused pharmaceutical company, Gland Pharma develops, manufactures, and markets complex injectables for global markets across the United States, Europe, Canada, Australia, and India. Established in Hyderabad in 1978, the company operates on a business-to-business model and serves customers in over 60 countries worldwide. Known for its expertise in complex injectable formulations, it maintains a strong presence across the value chain. Gland Pharma is promoted by Shanghai Fosun Pharma, a global pharmaceutical major.
Indian arm of South Korea's Mirae Asset Global Investments, one of Asia's largest asset managers. Manages over Rs 2.5 lakh crore in India across equity and hybrid funds. CIO Neelesh Surana has built a reputation for rigorous bottom-up stock selection with a long-term quality growth bias. Mirae Asset Emerging Bluechip Fund built a cult following before being closed to fresh investments due to size.